Dosage Forms

Topical drugs are attractive to patients, but these complex products pose challenges for formulators.

In-vitro and in-silico tools can help predict in-vivo outcomes for low-solubility drugs formulated as spray-dried dispersions.

Raman spectroscopy delivers real time, non-destructive process insights for critical process parameters to monitor pharmaceutical manufacturing.

Tests evaluated commercial rotary tablet presses to see how effectively they deal with problems such as poor flow, overlubrication, and capping.

Dosage-level authentication provides an added digital layer of security for pharmaceutical companies to ensure their products are not exposed to falsification.

AstraZeneca has released the results of its primary analysis of the Phase III trial data evaluating its COVID-19 vaccine.

Smart packaging opens doors to new products for diagnosis and treatment of eye problems.

With funding from the federal government, Merck will expand capacity to produce J&J’s COVID-19 vaccine.

In a pandemic, genetic vaccines offer several advantages over traditional approaches.

RDIF has announced that the Sputnik V vaccine for COVID-19 has been approved in Slovakia under the emergency use authorization procedure.

Distribution of the first one-dose vaccine for COVID-19 to start in early March.

Aprecia's compression-free 3DP manufacturing platform and Glatt’s multiparticulate technologies offer solutions to pharmaceutical dosage design challenges.

The EC has granted marketing authorization to Celltrion Healthcare for its adalimumab biosimilar, Yuflyma (CT-P17).

Rapid growth in biologics and increasing complexity of new compounds are some of the factors driving development of innovative delivery solutions.

Advanced manufacturing technologies are available, but challenges need to be addressed.

The EC intends to get tougher on issues such as reliability of drug supplies, particularly essential medicines.

Best practices can help ensure supply chain flexibility and viability for biologic drugs in clinical trials.

The dispute between the European Commission (EC) of the European Union and pharmaceutical company AstraZeneca continues.

Although a necessity, companies must strike a critical balance between protecting innovations with IP and providing affordable access to medicines.

Intravacc and Cristal Therapeutics have entered into a strategic collaboration for the development of novel vaccine programs against human diseases.

Amid pressure to get more vaccines administered faster, FDA pushes back against changes in dosing regimens.

FDA approval rate speeds up despite COVID-19 complications.

The right partner can help companies overcome key formulation challenges for biologic drugs.

Shutting down the COVID-19 pandemic requires a global, selfless effort.

Administration of the COVID-19 vaccination from Oxford University and AstraZeneca is expected to begin in the UK in early 2021.

Moderna’s mRNA vaccine to prevent COVID-19 disease is granted FDA Emergency Use Authorization and CDC recommendation.

A decision by the European Commission on conditional marketing authorization for the European Union’s first COVID-19 vaccine is expected soon.

A newly developed polymer, DynaShield, may have the capability to ensure global access for COVID-19 treatment and prevention.

Committee recommends Emergency Use Authorization of first mRNA-based COVID-19 vaccine; FDA approval is pending.

Evonik offers lipid nanoparticles for gene-based drug development and manufacturing.